Clinical Outcomes of a Treat and Extend Regimen with Intravitreal Aflibercept Injections in Patients with Diabetic Macular Edema: Experience in Clinical Practice.

Published on Mar 1, 2020in Ophthalmology and therapy
· DOI :10.1007/S40123-019-00224-X
Beverley Curry2
Estimated H-index: 2
(Hobart Corporation),
Paul G. Sanfilippo15
Estimated H-index: 15
(University of Melbourne)
+ 2 AuthorsNitin Verma7
Estimated H-index: 7
Sources
Abstract
Introduction Treat-and-extend (TE ‘as needed’) regimens of intravitreal anti-vascular endothelial growth factor (VEGF) treatment have been found to reduce the injection burden on patients and improve the cost effectiveness of the treatment of macular edema. The aim of this study was to assess the effectiveness of a T&E regimen of aflibercept, in a clinical setting, in patients with diabetic macular edema (DME) who were either intravitreal anti-VEGF therapy naive or with minimal exposure to anti-VEGF (≤ 6 treatments) in the previous 12 months.
📖 Papers frequently viewed together
2 Citations
1 Citations
References26
Newest
#1Bobak Bahrami (Vision-Sciences, Inc.)H-Index: 7
#2Thomas Hong (Vision-Sciences, Inc.)H-Index: 18
Last. Andrew Chang (Vision-Sciences, Inc.)H-Index: 20
view all 4 authors...
PURPOSE: To evaluate functional and anatomical outcomes after a switch from intravitreal bevacizumab to aflibercept in patients with persistent diabetic macular edema. METHODS: Prospective, single-arm, open-label clinical trial of patients with persistent diabetic macular edema, despite previous treatment with bevacizumab. Five loading doses of intravitreal aflibercept were administered every 4 weeks with subsequent injections administered every 8 weeks. Patients were reviewed every 4 weeks, and...
12 CitationsSource
#1David A EichenbaumH-Index: 7
#2Emily DuerrH-Index: 1
Last. Scott M PollackH-Index: 1
view all 4 authors...
BACKGROUND AND OBJECTIVE: Compare fixed monthly dosing of ranibizumab to treat-and-extend (TE 90% confidence interval). The average change from baseline BCVA was not statistically significantly different at any timepoint. At M24, the median number of injections in the monthly and TE49:e191-e197.].
3 CitationsSource
Purpose: To assess the effectiveness and safety of intravitreal aflibercept in clinically significant diabetic macular edema (DME) in daily clinical practice. Methods: Prospective, open-label, single-center study. Anti-vascular endothelial growth factor naive patients with clinically significant DME received intravitreal injections of aflibercept 2 mg, five monthly doses followed by a fixed schedule every 2 months for 12 months. The mean change in best-corrected visual acuity (BCVA) (Early Treat...
10 CitationsSource
#1Rita LaiginhasH-Index: 5
#2Marta Inês SilvaH-Index: 4
Last. Manuel Falcão (University of Porto)H-Index: 15
view all 9 authors...
Purpose To evaluate functional and anatomical outcomes after aflibercept in patients with diabetic macular edema (DME) with poor response to bevacizumab.
19 CitationsSource
#1Stuart KeelH-Index: 15
#2Jing XieH-Index: 29
Last. Mohamed DiraniH-Index: 31
view all 6 authors...
Purpose To determine the prevalence of and factors associated with diabetic retinopathy (DR) among non-Indigenous and Indigenous Australian adults with self-reported diabetes. Design Population-based cross-sectional study. Participants Non-Indigenous Australians (50–98 years of age) and Indigenous Australians (40–92 years of age) with known diabetes. Methods Diabetes was determined based on self-report of previous diagnosis of the disease. Nonmydriatic fundus photographs were obtained of each ey...
24 CitationsSource
#1Yen-Yi Chen (Memorial Hospital of South Bend)H-Index: 3
#3Jia-Kang WangH-Index: 4
To investigate the short-term efficacy and safety of intravitreal aflibercept in a case series of patients with diabetic macular edema (DME) refractory to ranibizumab or bevacizumab.A retrospective chart review.From September 2013 to March 2016, we identified patients with DME who developed resistance to bevacizumab or ranibizumab. Three monthly intravitreal aflibercept injections were administered in refractory cases. Nonresponse to aflibercept was defined as a paradoxical increase in central f...
20 CitationsSource
#1Masahiko SugimotoH-Index: 14
#2Atsushi IchioH-Index: 3
Last. Mineo KondoH-Index: 53
view all 4 authors...
To determine the efficacy of the treat and extend (TAE) protocol with intravitreal bevacizumab (IVB) for managing diabetic macular edema (DME). Retrospective, single-center study. For this retrospective study, 42 eyes of 42 patients were initially treated with 3 consecutive monthly IVB injections (loading phase), after which they were selected for different additional therapies. For the TAE protocol, the baseline treatment interval was selected to be 8 weeks and was sequentially lengthened by 2 ...
9 CitationsSource
#1John F. PayneH-Index: 18
#2Charles C. Wykoff (Houston Methodist Hospital)H-Index: 41
Last. David M. Brown (Houston Methodist Hospital)H-Index: 42
view all 6 authors...
Purpose To compare monthly dosing with a treat and extend algorithm using ranibizumab 0.3 mg with and without angiography-guided macular laser photocoagulation for center-involving diabetic macular edema (DME). Design Multicenter, prospective, randomized clinical trial. Participants A total of 150 eyes from 116 subjects were randomized into 3 cohorts: Monthly (n = 30), TReat and EXtend without macular laser photocoagulation (TREX; n = 60), and treat and extend with angiography-GuIded macular LAs...
40 CitationsSource
#1Lee M. Jampol (NU: Northwestern University)H-Index: 78
#2Adam R. GlassmanH-Index: 47
Last. Allison R. AyalaH-Index: 10
view all 5 authors...
Importance Post hoc analyses from the Diabetic Retinopathy Clinical Research Network randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema (DME) might influence interpretation of study results. Objective To provide additional outcomes comparing 3 anti–vascular endothelial growth factor (VEGF) agents for DME. Design, Setting, and Participants Post hoc analyses performed from May 3, 2016, to June 21, 2016, of a randomized clinical trial performed ...
31 CitationsSource
10 CitationsSource
Cited By9
Newest
#1Maja Szymanska (Imperial College London)
#2Daanyaal Mahmood (Imperial College London)
Last. Maria Francesca Cordeiro (Imperial College London)H-Index: 25
view all 4 authors...
Diabetic retinal disease remains one of the most common complications of diabetes mellitus (DM) and a leading cause of preventable blindness. The mainstay of management involves glycemic control, intravitreal, and laser therapy. However, intravitreal therapy commonly requires frequent hospital visits and some patients fail to achieve a significant improvement in vision. Novel and long-acting therapies targeting a range of pathways are warranted, while evidence to support optimal combinations of ...
Source
#1Patricia Take (GAU: University of Göttingen)
#2Carolin Alisa Dittmann (GAU: University of Göttingen)
Last. Sebastian Bemme (GAU: University of Göttingen)H-Index: 5
view all 8 authors...
Die regelmasige Therapie mittels intravitrealer operativer Medikamentenapplikation (IVOM) und die damit verbundenen Kontrolluntersuchungen stellen fur viele Patienten eine grose Herausforderung dar, die bis zum Behandlungsabbruch fuhren kann. Das modifizierte blockweise Treat-and-Extend(TAE)-Schema verfolgt das Ziel, mit moglichst wenigen Kontrollvisiten stabile Netzhaut- und Visusbefunde zu erreichen und dadurch die Belastung der Patienten zu minimieren. Diese monozentrische retrospektive Studi...
Source
Source
#1Takao Hirano (Shinshu University)H-Index: 11
#2Yuichi Toriyama (Shinshu University)H-Index: 15
Last. Toshinori Murata (Shinshu University)H-Index: 20
view all 13 authors...
This prospective, open-label, single-arm, non-randomized clinical trial, assessed the efficacy of a 2-year treat-and-extend (T&E) regimen involving intravitreal aflibercept injection (IAI), with the longest treatment interval set to 16 weeks, and adjunct focal/grid laser in diabetic macula edema (DME) patients. We examined 40 eyes (40 adults) with fovea-involving DME from 8 Japanese centers between April 2015 and February 2017. Participants received IAI with an induction period featuring monthly...
1 CitationsSource
#1Takao Hirano (Shinshu University)H-Index: 11
#2Yuichi Toriyama (Shinshu University)H-Index: 15
Last. Toshinori Murata (Shinshu University)H-Index: 20
view all 13 authors...
PURPOSE To investigate the efficacy and safety of a treat-and-extend (T&E) regimen using aflibercept (Eylea) for diabetic macular edema (DME). STUDY DESIGN Prospective, open-label, multicenter, single-arm, nonblinded clinical study. METHODS Forty eyes of 40 patients with DME received a T&E regimen of intravitreal aflibercept injection (IAI) with the longest treatment interval set to 16 weeks and adjunct focal/grid laser for 1 year. An intent-to-treat analysis was performed using the same last-ob...
Source
#1Daniele VerittiH-Index: 14
#2Valentina SaraoH-Index: 14
Last. Paolo LanzettaH-Index: 32
view all 4 authors...
Purpose This meta-analysis aims to summarize 12-month best-corrected visual acuity (BCVA) outcomes in response to anti-vascular endothelial growth factor (VEGF) therapy and dexamethasone implant for the treatment of diabetic macular edema (DME) and to identify factors affecting treatment response using evidence generated from meta-regression. Methods A systematic review of electronic databases was conducted to identify randomized controlled trials (RCTs) and real-life/observational studies that ...
1 CitationsSource
#1Yu Cheol Kim (KMU: Keimyung University)H-Index: 1
#2Jae Pil ShinH-Index: 17
Last. Ji Eun Lee (PNU: Pusan National University)H-Index: 19
view all 9 authors...
This study was performed to investigate the efficacy of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema (DME). This prospective, multicentre, interventional, single-arm, 104-week clinical trial included 48 patients with DME visual impairment. The patients' eyes received five consecutive intravitreal injections (2 mg aflibercept) every four weeks with two-week adjustments based on central subfield macular thickness (CSMT) changes. Injections were deferred when ...
2 CitationsSource
Last. Guisen ZhangH-Index: 3
view all 13 authors...
Background Diabetic macular edema (DME) can cause severe vision impairments for patients with diabetes. Recently, Conbercept has shown efficacy on DME with 3-monthly loading dose injection and pro re nata (PRN, 3+PRN) thereafter in retrospectivetrials. Furthermore, there are some other approaches have been recommended such as 2mg bimonthly (2q8) after 5 initial doses, or Conbercept 0.5mg treat-and-extend, however, some patients still have recurrence of the disease after treatment. Therefore, in ...
1 CitationsSource
#1Ayse Gul Kocak Altintas (UHSA: University of Health Sciences Antigua)H-Index: 7
#2Cagri IlhanH-Index: 4
Last. mahmut cankurtaran (UHSA: University of Health Sciences Antigua)
view all 3 authors...
PURPOSE To evaluate the effects of epiretinal membrane (ERM) formation on the anatomic and functional results of subjects with diabetic macular edema (DME) who are receiving intravitreal aflibercept injections (IAIs). MATERIALS AND METHODS This retrospective comparative study includes 29 eyes with DME (Group 1) and 43 eyes with DME and ERM (Group 2). After three consecutive monthly 2.0 mg IAIs, subjects received monthly follow-ups and retreatment was performed if needed. Corrected visual acuity ...
Source